Essentially, the presence of these immune cells within the tumor microenvironment plays a pivotal role in how effectively the immune system can identify and attack cancer cells under the modulation of immunotherapies targeting checkpoint inhibitors like PD-1/PD-L1. The gene discussed is PDCD1; the disease is cancer.